#Japan #Kyoto #nanotechnology #Regenesome #IVS2026

Regenesome Showcases Innovative Nanoparticle Technology at IVS2026

On July 2, 2026, Regenesome Corporation, a subsidiary of Space Seed Holdings, presented at the IVS 2026 Startup Market. This major startup conference, organized by Headline Japan, took place at the Miyakome Messe in Kyoto. Regenesome exhibited its cutting-edge approach to deliver therapeutic nanoparticles across the blood-brain barrier (BBB), which has traditionally been a significant challenge in biomedical research.

Overview of the Exhibition

Regenesome's booth highlighted its advanced nanoparticle platform that aims to transport functional ingredients across this crucial barrier to enhance brain health and manage aging. This innovative approach aims to open dialogues with investors, corporate partners, and research institutions about its potential applications in aging control and health longevity.

Key Highlights from the Booth

1. Nanoparticles Designed for the Brain
The blood-brain barrier serves as a gatekeeper, selectively allowing substances to enter the brain while excluding others. Regenesome aims to revolutionize this by creating nanoparticles that encapsulate functional components suitable for brain delivery, which was detailed visually through posters and discussions with attendees.

2. Efficient Development Process
Regenesome presented how they are harnessing AI and laboratory automation to streamline the process from material discovery to application. By increasing the number of experiments conducted, the company believes it can expedite the development of this revolutionary technology.

3. Potential Applications
At the booth, the team explored diverse applications of their nanoparticle technology, including brain function support, extending health lifespan, and drug delivery systems (DDS) for pharmaceuticals. The discussions focused on how future research could clarify these applications, with Regenesome actively seeking partnerships for collaborative ventures to advance these initiatives.

Strategic Positioning of the Exhibition

Regenesome's mission is to solve aging-related challenges through biotechnology, aspiring to develop anti-aging and regenerative medicine technologies through nanoparticle applications. The company envisions providing essential technologies that could enable humans to extend their presence beyond Earth by 2040, effectively linking planetary health with space research.

Parent company Space Seed Holdings operates under the motto of turning science fiction into reality. They engage in autonomous research that spans both space and terrestrial applications, emphasizing areas like fermentation and biotechnology in extreme environments. Through Regenesome’s participation in IVS2026, the objective remains to bridge connections with the public and stakeholders regarding their pivotal research.

Future Directions

Following IVS2026, both Space Seed Holdings and Regenesome are committed to fostering discussions with potential collaborators, focusing on:

• - Expanding partnerships with institutions, corporations, and startups in the fields of longevity and regenerative medicine.
• - Initiating joint research and collaborations aimed at societal implementation of nanoparticle technologies for aging control and regenerative medicine.
• - Continuing efforts to link research in health longevity from Earth to space healthcare initiatives.

Details regarding specific collaborations will be shared as agreements are finalized.

CEO Insights

Kengo Suzuki, the CEO of both Regenesome and Space Seed Holdings, stated, "Delivering substances to the brain is a complex challenge that many researchers have faced, and the blood-brain barrier represents a significant hurdle. We are tackling this with the innovative approach of utilizing nanoparticles. During our time in Kyoto, we received insightful questions from investors and researchers alike, reminding us of the importance of translating technical language into something accessible to society. It is essential that we establish robust health technologies on Earth before we apply them in the lunar habitat projected for 2040."

About Regenesome

Regenesome focuses on providing innovative solutions for aging and regenerative medicine through the utilization of nanoparticles. With its headquarters and research lab established in Takagawa Gateway City, the company is accelerating healthcare initiatives under their brand ‘Saisei Lab’ while preparing for future expansions into medical fields, ultimately aiming to contribute to extending healthy life spans and humanity's pursuit of space exploration.

Visit Regenesome

About Space Seed Holdings

Space Seed Holdings is dedicated to making science fiction a reality through investment, research, and business creation within deep tech ecosystems. Their programs support the social implementation of fermentation and longevity technologies aimed at solving critical social issues, and they seek to ensure a critical supply of technologies necessary for human habitation in space by 2040.

Visit Space Seed Holdings